The latest news, announcements and press releases from Aitia Bio.
SOMERVILLE, Mass. and ESPOO, Finland, Sept. 25, 2024 /PRNewswire/ -- Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop new drugs, announced today that the companies have entered into agreement to create new Gemini Digital Twins to help in the fight against cancer.
Cancer is a critical global health issue, affecting millions of people worldwide and imposing a significant burden on healthcare systems. In 2022 alone, nearly 20 million new cancer cases were diagnosed, with 10 million lives lost to the disease1. The global cancer burden is projected to rise significantly, with new cases expected to reach 35 million annually by 2050 if current trends continue, driven by population aging and growth. This growing challenge underscores the urgent need for innovative treatments. The collaboration between Orion and Aitia to discover and develop new cancer drugs aims to address this need.
This is the News section of the company profile page for Aitia Bio on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
